PT  - JOURNAL ARTICLE
AU  - Michael Friedlander
AU  - Edward Trimble
AU  - Anna Tinker
AU  - David Alberts
AU  - Elisabeth Avall-Lundqvist
AU  - Mark Brady
AU  - Philipp Harter
AU  - Sandro Pignata
AU  - Eric Pujade- Lauraine
AU  - Jalid Sehouli
AU  - Ignace Vergote
AU  - Philip Beale
AU  - Rudd Bekkers
AU  - Paula Calvert
AU  - Lawrence Copeland
AU  - Ros Glasspool
AU  - Antonio Gonzalez-Martin
AU  - Dionysis Katsaros
AU  - Jae Won Kim
AU  - Brigitte Miller
AU  - Diane Provencher
AU  - Lawrence Rubinstein
AU  - Mostafa Atri
AU  - Alain Zeimet
AU  - Monica Bacon
AU  - Henry Kitchener
AU  - Gavin C.E. Stuart
TI  - Clinical Trials in Recurrent Ovarian Cancer
AID  - 10.1097/IGC.0b013e31821bb8aa
DP  - 2011 Apr 01
TA  - International Journal of Gynecologic Cancer
PG  - 771--775
VI  - 21
IP  - 4
4099  - http://ijgc.bmj.com/content/21/4/771.short
4100  - http://ijgc.bmj.com/content/21/4/771.full
SO  - Int J Gynecol Cancer2011 Apr 01; 21
AB  - The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?